|
Clinical relevance of Vav3.1 expression in ovarian cancer and involvement in mechanisms causing genuine multi-drug resistance. |
| |
|
Consulting or Advisory Role - AstraZeneca; PharmaMar |
Patents, Royalties, Other Intellectual Property - Oncotyrol |
Travel, Accommodations, Expenses - Amgen; AstraZeneca; PharmaMar; Roche |
| |
|
Employment - Pantec Biosolutions |
Patents, Royalties, Other Intellectual Property - Oncotyrol |
| |
|
Patents, Royalties, Other Intellectual Property - Oncotyrol |
| |
Dominik Georg Friedrich Wolf |
Patents, Royalties, Other Intellectual Property - Oncotyrol |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |